Todd Frederick, M.D. , Scientist; Director of Clinical Protocol Development and Liver Support Services at CPMC, Director of the Transplant Hepatology Fellowship Program

California Pacific CURRENTS: The online journal of CPMC Research Institute

Liver disease management and transplant
  • Multifactorial nature of hepatic encephalopathy

    Hypothesis of the multifactorial nature of hepatic encephalopathy. Various neurotoxins and neurotransmitters act independently or perhaps synergistically to cause astrocyte swelling and subsequent astrocyte dysfunction.

    Source: Reprinted from Frederick T. Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterol Hepatol N. Y. 2011;7(4 ):222-231. Used with permission.

+

Research Overview

  • Dr. Frederick is a transplant hepatologist with CPMC’s Liver Disease Management and Transplant Program, and he serves as Director of Clinical Protocols and Liver Support Services.
  • He investigates the pathophysiology and treatment of portal hypertension, hepatic encephalopathy, and liver support devices for acute and acute-on-chronic liver failure.
  • Author of numerous manuscripts, book chapters, and abstracts, Dr. Frederick leads clinical trials of treatments for hepatic encephalopathy, hepatitis B and C, liver failure, and the management of liver transplantation.

Training
 

Dr. Frederick received his M.D. from New York Medical College in Valhalla, New York.  He completed residency training in internal medicine and a fellowship in gastroenterology and liver transplantation at the University of California, San Diego.


 

Publication Search

Publications

Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, Ganger D, Jamil K, Pappas SC, REVERSE Study Investigators., Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology

Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P, ION-2 Investigators., Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med

Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW, ION-3 Investigators., Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med

Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP, Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol

Yimam KK, Merriman RB, Todd Frederick R, A rare case of acute hepatitis B virus infection causing guillain-barré syndrome. Gastroenterol Hepatol (N Y)

VIEW ALL
Todd Frederick, M.D. , Scientist; Director of Clinical Protocol Development and Liver Support Services at CPMC, Director of the Transplant Hepatology Fellowship Program
Primary Research Interests
  • Treatment of acute liver failure
  • Management of hepatitis B and C
  • Liver transplant

Liver Failure and Liver Transplant Clinical Trials